
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah's positive outlook is bolstered by a noteworthy gross margin of over 73% in the recent quarter, an increase from 62% in the prior quarter, indicating effective cost management amidst growing sales momentum. The potential approval of the Genio system in the U.S. is anticipated to significantly drive revenue growth, supported by trained physicians and a doubling of sales representatives by the end of 2025. Additionally, the favorable results from the DREAM trial and insights from prior market surveys suggest that the Genio system is well-positioned to capture market share in the expanding hypoglossal nerve stimulation sector.
Bears say
Nyxoah SA faces significant challenges in the European market, which may hinder its growth and penetration in the competitive landscape for sleep-disordered breathing treatments. The company's fourth-quarter 2024 revenue of €1.3 million fell short of expectations, missing estimates of €2.0 million and €1.9 million, indicating potential weaknesses in sales performance. Additionally, factors such as regulatory approval issues, inadequate reimbursement, and emerging competition further exacerbate the concerns regarding the company's financial outlook and overall viability in the market.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares